独特的基序序列早期诊断子痫前期

IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Farizky Martriano Humardani , Agustina Tri Endharti , Ratih Asmana Ningrum , I Wayan Arsana Wiyasa , Lisa Thalia Mulyanata , Yulanda Antonius , Jonathan Jonathan , Sulistyo Emantoko Dwi Putra
{"title":"独特的基序序列早期诊断子痫前期","authors":"Farizky Martriano Humardani ,&nbsp;Agustina Tri Endharti ,&nbsp;Ratih Asmana Ningrum ,&nbsp;I Wayan Arsana Wiyasa ,&nbsp;Lisa Thalia Mulyanata ,&nbsp;Yulanda Antonius ,&nbsp;Jonathan Jonathan ,&nbsp;Sulistyo Emantoko Dwi Putra","doi":"10.1016/j.cca.2025.120339","DOIUrl":null,"url":null,"abstract":"<div><div>Preeclampsia (PE) is a disease that significantly impacts both maternal and infant health with its prevalence varying across different ethnicities. Current diagnostic methods for PE typically identify the condition after 20 weeks of gestation, often when the disease has already manifested and reached an advanced stage. The situation underscores the urgent need for early biomarkers capable of effective screening and diagnosis. Our review addresses this challenge by utilizing bioinformatics approaches as an alternative method prior to preclinical and clinical studies. Specifically, we focus on FRAGmentomics-based Methylation Analysis (FRAGMA), targeting the CGCGCGG sequence motif for methylation studies in cell-free DNA (cfDNA). Since cfDNA is largely derived from the placenta, the FRAGMA approach is particularly promising, given that the primary pathophysiology of PE originates in the placenta, and methylation patterns are unique to specific tissues. In the previous research, we identified 66 genes containing this sequence motif that are implicated in the pathophysiology of PE, and only six genes – FN1, ITGA2, ITGA5, ITGB1, ITGB3, and VWF – show potential as early detection biomarkers for PE. These genes still require further investigation to confirm their utility as biomarkers for PE in the future studies.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"574 ","pages":"Article 120339"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unique motif Sequences for early diagnosis of preeclampsia\",\"authors\":\"Farizky Martriano Humardani ,&nbsp;Agustina Tri Endharti ,&nbsp;Ratih Asmana Ningrum ,&nbsp;I Wayan Arsana Wiyasa ,&nbsp;Lisa Thalia Mulyanata ,&nbsp;Yulanda Antonius ,&nbsp;Jonathan Jonathan ,&nbsp;Sulistyo Emantoko Dwi Putra\",\"doi\":\"10.1016/j.cca.2025.120339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Preeclampsia (PE) is a disease that significantly impacts both maternal and infant health with its prevalence varying across different ethnicities. Current diagnostic methods for PE typically identify the condition after 20 weeks of gestation, often when the disease has already manifested and reached an advanced stage. The situation underscores the urgent need for early biomarkers capable of effective screening and diagnosis. Our review addresses this challenge by utilizing bioinformatics approaches as an alternative method prior to preclinical and clinical studies. Specifically, we focus on FRAGmentomics-based Methylation Analysis (FRAGMA), targeting the CGCGCGG sequence motif for methylation studies in cell-free DNA (cfDNA). Since cfDNA is largely derived from the placenta, the FRAGMA approach is particularly promising, given that the primary pathophysiology of PE originates in the placenta, and methylation patterns are unique to specific tissues. In the previous research, we identified 66 genes containing this sequence motif that are implicated in the pathophysiology of PE, and only six genes – FN1, ITGA2, ITGA5, ITGB1, ITGB3, and VWF – show potential as early detection biomarkers for PE. These genes still require further investigation to confirm their utility as biomarkers for PE in the future studies.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"574 \",\"pages\":\"Article 120339\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125002189\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002189","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

子痫前期(PE)是一种严重影响母婴健康的疾病,其患病率在不同种族之间存在差异。目前的PE诊断方法通常在妊娠20周后确定病情,通常是在疾病已经表现出来并达到晚期的时候。这种情况强调了迫切需要能够有效筛查和诊断的早期生物标志物。我们的综述通过利用生物信息学方法作为临床前和临床研究之前的替代方法来解决这一挑战。具体来说,我们专注于基于片段组学的甲基化分析(FRAGMA),针对CGCGCGG序列基序进行无细胞DNA (cfDNA)的甲基化研究。由于cfDNA主要来自胎盘,考虑到PE的主要病理生理起源于胎盘,甲基化模式对特定组织是独特的,FRAGMA方法特别有希望。在之前的研究中,我们鉴定了66个包含该序列基序的基因,这些基因与PE的病理生理有关,其中只有6个基因(FN1、ITGA2、ITGA5、ITGB1、ITGB3和VWF)显示出作为PE早期检测生物标志物的潜力。在未来的研究中,这些基因仍需要进一步的研究来证实它们作为PE生物标志物的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unique motif Sequences for early diagnosis of preeclampsia
Preeclampsia (PE) is a disease that significantly impacts both maternal and infant health with its prevalence varying across different ethnicities. Current diagnostic methods for PE typically identify the condition after 20 weeks of gestation, often when the disease has already manifested and reached an advanced stage. The situation underscores the urgent need for early biomarkers capable of effective screening and diagnosis. Our review addresses this challenge by utilizing bioinformatics approaches as an alternative method prior to preclinical and clinical studies. Specifically, we focus on FRAGmentomics-based Methylation Analysis (FRAGMA), targeting the CGCGCGG sequence motif for methylation studies in cell-free DNA (cfDNA). Since cfDNA is largely derived from the placenta, the FRAGMA approach is particularly promising, given that the primary pathophysiology of PE originates in the placenta, and methylation patterns are unique to specific tissues. In the previous research, we identified 66 genes containing this sequence motif that are implicated in the pathophysiology of PE, and only six genes – FN1, ITGA2, ITGA5, ITGB1, ITGB3, and VWF – show potential as early detection biomarkers for PE. These genes still require further investigation to confirm their utility as biomarkers for PE in the future studies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinica Chimica Acta
Clinica Chimica Acta 医学-医学实验技术
CiteScore
10.10
自引率
2.00%
发文量
1268
审稿时长
23 days
期刊介绍: The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信